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Inhibition Studies of Porphobilinogen Synthase
from Escherichia coli Differentiating between the
Two Recognition Sites
Fre´de´ric Stauffer,[b] Eleonora Zizzari,[a] Caroline Engeloch-Jarret,[c]
Jean-Philippe Faurite,[a] Janette Boba´lova´,[d] and Reinhard Neier*[a]
Porphobilinogen synthase condenses two molecules of 5-amino-
levulinate in an asymmetric way. This unusual transformation
requires a selective recognition and differentiation between the
substrates ending up in the A site or in the P site of porphobilinogen
synthase. Studies of inhibitors based on the key intermediate first
postulated by Jordan allowed differentiation of the two recognition
sites. The P site, whose structure is known from X-ray crystallo-
graphic studies, tolerates ester functions well. The A site interacts
very strongly with nitro groups, but is not very tolerant to ester
functions. This differentiation is a central factor in the asymmetric
handling of the two identical substrates. Finally, it could be shown
that the keto group of the substrate bound at the A site is not only
essential for the recognition, but that an increase in electrophilicity
of the carbon atom also increases the inhibition potency consid-
erably. This has important consequences for the recognition
process at the A site, whose exact structure is not yet known.
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Introduction
The biosynthesis of the tetrapyrrolic skeleton of the “pigments of
life”[1] has fascinated chemists and biologists since their discov-
ery and their structure determination.[2] Starting from the first
dedicated intermediate in the biosynthesis of the tetrapyrrolic
dyes, 5-aminolevulinic acid (ALA, 1), the macrocyclic skeleton is
synthesized in only three enzyme-catalyzed steps in a highly
convergent way (Scheme 1).[3] Two condensation steps lead first
to porphobilinogen (PBG, 2)[4, 5] and then to the linear com-
pound hydroxybilane, which cyclizes and rearranges to the
common precursor of all pigments of life, uroporphyrinogen III
(Uro III, 3).[6] The synthetic efficiency of the biosynthesis and the
importance of the tetrapyrrolic cofactors have further enhanced
the interest in studies of the biosynthetic pathway.
In this three-step sequence, the first step, formation of PBG (2),
cannot easily be imitated by chemists (Scheme 2).[7–14] In contrast
to this observation, the tetramerization and cyclization have
been shown to occur in the presence of acids, yielding the
natural regioisomer, Uro III (3), as the major product.[15] However,
the chemical condensation of ALA (1) in the presence of oxygen
gives an appreciable amount of the oxidized pyrazine 4.[16] In the
absence of oxygen the symmetric diimine is formed as the major
product and a small amount of pseudo-PBG has been observed
as a side product.[17, 18] Treating ALA (1) with Amberlite TR-45 for
a long time has been reported to give some PBG (2).[16, 17]
Porphobilinogen synthase (PBGS, E.C. 4.2.1.24), also called
5-aminolevulinate dehydratase (ALAD), the enzyme responsible
for the nonsymmetrical condensation of the two molecules of
ALA (1), has been isolated and studied for a long time.[19] PBGS is
widely distributed in bacteria, plants, animals, and humans.[14] All
PBGSs studied so far share a considerable degree of homology[20]
and most enzymes were shown to be present as octamers.[21, 22]
In early studies it could be shown that a Schiff base intermediate
between ALA (1) and a lysine side chain located in the active site
of PBGS can be trapped by reduction with NaBH4.[23] This result
was one of the important motivations to draw a close
mechanistic analogy between PBGS and the aldolases of
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Scheme 1. The convergent biosynthesis of uroporphyrinogen III (3) from eight
molecules of 5-aminolevulinic acid (1), as determined by the biosynthetic and
synthetic studies performed in the groups of Akhtar, Arigoni, Battersby,
Eschenmoser, Jordan, Müller, Scott, Shemin, and Thauer (for a review of this
pathway see ref. [69]). On the left, the retrosynthetic tree for the transformation of
eight molecules of 5-aminolevulinic acid (1) into four molecules of porphobili-
nogen (2) and finally into one molecule of uroporphyrinogen III (3) is symbolically
represented.
N
HNH2
HOOC
COOH
H2N
O
COOH
O
NH2
COOH
N
N
COOH
HOOC
NaOH
PBG synthase
PBG (2)
ALA (1)
_ 2 H2O
_ 2 H2O
O2
+
4
Scheme 2. The dichotomy between the biosynthetic and the chemical dimeri-
zation of 5-aminolevulinic acid (1).
type I.[23] The influence on the catalytic activity of PBGS of
bivalent metal ions like ZnII and MgII was recognized and
intensively studied.[24] For the ZnII-containing enzymes, the three
cysteine residues binding the metal ion could be identified.[25]
For the MgII-containing enzymes it was assumed that the
aspartate-rich region replacing the zinc finger element would
form the ligands for the metal ion. One of the most important
findings was the determination of the sequence of recognition
of the two substrates. Using an elegant pulse-labeling experi-
ment Jordan and Seehra could demonstrate that the first ALA (1)
recognized by PBGS will form the propionic acid side chain of
PBG (2).[26] ALA (1) forming the propionic acid side chain will first
interact with the P site of the enzyme, and the second ALA
molecule will interact with the A site.[26] Based on this finding an
alternative mechanism for the transformation of ALA (1) to PBG
(2) was proposed.[6, 26, 27] An impressive effort allowed character-
ization of the complexes between modified PBGS and its natural
substrate ALA (1) by sophisticated NMR spectroscopic techni-
ques.[28] These spectroscopic measurements identified the Schiff
base intermediate formed with the P site of the enzyme and
gave indications about the protonation state of both this
enzyme – substrate complex and the product – enzyme com-
plex.[28, 29]
Molecular biology has allowed the determination and com-
parison of the sequences of PBGSs from many sources.[20] More
importantly, it became possible to overexpress this enzyme. In
recent years the high-resolution X-ray crystallographic structures
of PBGSs from three different sources have been publish-
ed.[25, 30–32] The structures of the enzymes with an empty active
site and of the enzymes containing one of the classical inhibitors,
levulinic acid, are now available (Brookhaven Protein Data Bank,
PDB entries 1aw5, 1ylv, 1b4k). The overall structures of the PBGSs
from the three sources Saccharomyces cerevisiae, Escherichia coli,
and Pseudomonas aeruginosa are very similar. The three enzymes
crystallize as an octamer, which is a tetramer of a dimer. The
overall structure of the protein corresponds to a TIM barrel
(Figure 1 A).[25, 33] The N-terminal arm is responsible for a large
number of contacts between the two units of the homodimer.
The ZnII ion present in the active site is coordinated by three
cysteines (Cys 133, Cys 135, and Cys 143; numbering for PBGS
from S. cerevisiae). The X-ray crystallographic structure of PBGS
showed not only the lysine residue (Lys 263 for PBGS from
S. cerevisiae) identified by the reduction with NaBH4 , but also the
presence of a second lysine residue in the active site (Lys 210,
numbering for PBGS from S. cerevisiae). The structures contain-
ing levulinic acid at the P site clearly indicated the formation of
the Schiff base between the carbonyl group and the e-amino
group of Lys 263 (PBGS from S. cerevisiae) and the hydrogen
bonding of the carboxylate to Tyr 329 and Ser 290 (numbering
for PBGS from S. cerevisiae).
The structures of PBGS not containing the inhibitor bound to
the active site were not well resolved in the region of the amino
acids 220 to 233. When the inhibitor was bound to the enzyme
this lid covers tightly the active site (see Figures 1 B and C). The
structure of PBGS from P. aeruginosa could be determined at a
high resolution.[30] The overall structure is similar to those
observed for the two other PBGSs resolved. Within the same
crystal the two active sites of the asymmetric dimer were
occupied by a single molecule of levulinic acid, but only one site
was completely closed by the lid. Only one MgII ion is present per
dimer. The MgII ion is not positioned at the active site, but at the
interface between the two subunits.[30] A catalytic role has been
attributed to the ZnII ions present in the active site. The MgII ion
2
must play another role and an allosteric interaction of the metal
ion has been proposed that induces the complete closure
of the lid.[30]
Right from the beginning of the studies of PBGS, inhibition
experiments were undertaken to explore the active site of the
enzyme.[34–36] Our group has studied the inhibition
behavior of PBGS isolated from Rhodobacter sphaer-
oides and from E. coli.[14, 37] The goal of our systematic
studies is to characterize the recognition sites of
PBGS sufficiently, so that adequate analogues of the
postulated intermediates can be synthesized and
their inhibition behavior can be tested. The long-
term objective is to obtain information relevant for
the detailed understanding of the mechanism and at
the same time to have a collection of adequate
inhibitors available suited for cocrystallization with
the enzyme.
Several groups have made significant contribu-
tions to our knowledge of the inhibition behavior of
substrate analogues.[14, 38, 39] These systematic stud-
ies have been facilitated by the availability of large
quantities of recombinant PBGS from organisms like
E. coli, S. cerevisiae, and Pisum sativum.[38] Only
recently we could show that the kinetics of PBGS
depend highly on the concentration of the natural
substrate used during the test.[41] Using substrate
concentrations between 4 and 80 mM a parabolic
curve is observed if an inverse plot (1/[S] against 1/v)
is used to analyze the experimental results. This
parabolic curve is compatible with a mechanism in
which two substrate molecules are sequentially
recognized at the active site of the enzyme (Fig-
ure 2). The Michaelis – Menten constants for the two
sites can be calculated to be KM,1 4.6 mM and KM,2
66 mM. If, however, substrate concentrations be-
tween 80 and 400 mM are used, simple Michaelis –
Menten kinetics are observed. This behavior has
been interpreted as the consequence of saturating
the first recognition site of PBGS and thereby
observing only the competition between binding
of our inhibitors and the recognition of the second
substrate by the enzyme saturated at the P site with
the natural substrate.
This peculiarity of PBGS allows one to draw
conclusions not only from the size of the inhibition
constants, but also from the change in inhibition
behavior. We interpret pure competitive inhibition
as a consequence of competition between the
natural substrate and the inhibitor for the A site of
the enzyme. Observation of mixed or uncompetitive
inhibition is a clear sign for a more complex
interaction; probably the inhibitor competes with
the natural substrate also for the P site. In the
absence of functional groups capable of forming
irreversible covalent bonds with the enzyme, slow
binding or even irreversible inhibition is an indica-
tion that several functional groups interact syner-
gistically with the amino acids of the active site. It is probable
that interactions at both sites of the enzyme, the A and the P site,
are responsible for this behavior.
PBGS will recognize two d-amino acids 1 first, which will be
transformed into an aromatic amino dicarboxylic acid 2. What-
Figure 1. A: Structure of PBGS from S. cerevisiae. The TIM barrel fold and the N-terminal arm
are clearly visible in the schematic presentation of the secondary structure elements. The two
lysines of the active site are colored in green (Lys 263) and purple (Lys 210); the two ZnII ions are
colored in blue. B: Space-filling model of PBGS without an inhibitor bound in the active site. The
lid part of the enzyme is colored in orange. The active site is accessible from the outside. C: The
structure of PBGS bound to levulinate. The lid is much more structured and covers the active site
almost completely . The two lysine residues of the active site are not accessible from the outside.
All structures were drawn with the program SYBYL 6.6 (TRIPOS Inc. , St. Louis) by using the
coordinates deposited in the Brookhaven Protein Databank (PDB entries 1aw5 and 1ylv, which
were determined at 2.3 and 2.15  resolution, respectively).
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ever is the mechanism of this transformation, at one point an
aliphatic dicarboxylic acid must be present as intermediate. In a
recent study we have shown that aliphatic g-ketodicarboxylates
are recognized by PBGS.[41] The chain length is an important
factor determining the inhibition behavior as well as the size of
the inhibition constant. 4-Oxopimelic acid is a moderate
competitive inhibitor, whereas 4-oxosebacic acid is an irrever-
sible inhibitor. We have interpreted this significant change in the
inhibition behavior as a function of the chain length
as a hint in favor of the mechanism first proposed by
Jordan (Scheme 3, mechanism Jordan I).[41]
Concentrating the mechanistic analysis on the key
step, which will connect for the first time the two
identical substrates, thereby creating the differentia-
tion between the two ALA molecules (1), three
proposals have been discussed. The first proposal
made by Shemin over 30 years ago used a close
analogy with the aldolases of type I as a guideline.
The central point of this mechanism is the formation
of a Schiff base intermediate between the enzyme
and the A-site substrate. This Schiff base is then
transformed into its corresponding enamine, which
has the correct reactivity to form the crucial CÿC
bond leading to the intermediate 5. Despite its
attractiveness from the mechanistic point of view,[23]
this proposal has been largely dismissed due to the
fact that Shemin proposed the recognition of the
A-site substrate first. This is clearly not compatible
with the results of Jordan’s pulse-labeling experi-
ments. The formation of the same CÿC bond, leading
to the intermediate 6 as the key compound joining
the two substrate molecules for the first time, has
been proposed by Jordan later (Jordan II mecha-
nism).[6] His proposal incorporates the sequence of
recognition events. The mechanism postulated by
Jordan first (Jordan I mechanism) proposes the formation of the
key intermediate 7, which involves the Schiff base between the
two reacting starting materials. This mechanism has the
advantage of following the mechanism proposed for the Knorr
pyrrole synthesis.[40] However, it has been recognized that
stereoelectronically this ring closure reaction is not favorable.[42]
It is worth mentioning that it has not been possible to trap this
second Schiff base despite considerable efforts.[43]
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Figure 2. Mechanistic and kinetic interpretation of the fact that a Michaelis – Menten kinetics is observed for the inhibition of PBGS.
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Results and Discussion
Studies with substrate analogues showing competitive inhib-
ition behavior had shown that for a good recognition the g-keto
function was necessary.[44, 45] Replacing the amino group of the
substrate had no significant effect. This result is compatible with
our kinetic interpretation postulating the interaction of these
inhibitors at the A site. The amino group at this position does not
undergo any change during the reaction. Finally, the carboxylate
is important for a good recognition. Replacing the carboxylate
by an ester group reduces the affinity considerably, usually KI
increases by at least a factor of 10 – 20. The carboxylate function
can be substituted by a nitro group and a considerable increase
in the affinity can be observed: KI decreases by a factor of about
100. Synthesizing and testing dicarboxylates and analogues
thereof, which contain the three functional groups mentioned
above, should allow analysis not only of the recognition
selectivity at the A site, but also at the P site (Scheme 4).
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Scheme 4. A comparison of the Jordan I intermediate with the simplified
structures was used to construct families of inhibitors. The inhibition potency of
the substrate analogues 8, 17, and 34 has been determined for comparison with
the inhibition constants of the more complex analogues of intermediates.[37, 45, 68]
To work out this analysis, the inhibitors have to be recognized
at both sites and we have to be able to predict the orientation of
the inhibitor in the active site. The analysis of all the reported
inhibition studies of PBGS indicates that replacing the keto
function of an inhibitor reduces substantially its affinity for the
A site. We hoped, however, that the A site would be more
tolerant to the introduction of an amide function than the P site,
where a keto function is necessary to form the Schiff base.
Introducing an amide function at this position could have
additional advantages (Scheme 5). The key intermediate of the
Jordan I mechanism possesses an iminium ion connecting the C4
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Scheme 5. Comparison of intermediates postulated in the Jordan I mechanism
(top row) with the analogues containing an amide function as the central part
(bottom row).
atom of the A-site ALA with the amino group of the P-site ALA.
Furthermore, in the next step in the formation of the enamine,
the C4 atom stays sp2-hybridized. This double-bond character
was not completely imitated by using the dioxosebacic acid as
inhibitor. An amide function should at least partially imitate this
double-bond character. At the same time the amide group
mimics also the charge distribution found in the iminium ion and
to some extent also the polarity that is found when the amine
group of the P-site substrate is attacking the carbonyl function of
the A-site substrate. The major problem in using an amide
function resides in the fact that there is a restricted rotation
around this partial C-N double bond. It is known that the s-trans
conformer is preferred in solution for secondary amides, whereas
we have to suppose that the diacids are bound in a conforma-
tion that is close to the relative position of the two carboxylate
groups as they are found in the product.
In view of these arguments we decided to study a series of
substrate analogues first to obtain data which should allow to
evaluate the importance of the replacement of the g-keto
function by an amide group (Tables 1 and 2). The comparison of
the inhibition potency of the nitro compounds (see Table 2) with
the corresponding carboxylates (see Table 1) shows that in three
out of five cases the nitro compound is better recognized than
the carboxylate. The difference between the nitro compound
and the carboxylates is usually considerable. In the case of
compounds 17 and 8, the nitro compound is almost 80 times
better recognized than the carboxylate. The difference for the a-
fluoroketones 18 and 9 is, however, rather small : Recognition of
the nitro compound is only better by a factor of four. The
introduction of an a-fluoro substituent increases the electro-
philicity of the carbon atom of the ketone and should reduce the
nucleophilicity of its oxygen atom. The inhibition potency seems
to be considerably increased by this change in electron density.
This comes as a surprise, because most hypotheses published so
far have assumed that the keto function acts as a ligand for a
Lewis acid.[46–49] It has been speculated that ZnII would function
as the Lewis acid, which activates the ketone and facilitates
thereby the transformation into the enol or the enolate ion. The
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observation of this strong increase in inhibition potency is not in
accordance with these postulated interactions with the enzyme
active site. The combination of two factors that individually
increase the inhibition potency seems not to be additive. The
nitro fluoro compound 18 shows only a slight decrease in KI
compared to the nitroketone 17, whereas the introduction of the
fluoro substituent into levulinic acid decreases the KI consid-
erably: A change of KI from 2 200 mM for 8 to 85 mM for compound
9 is observed. Changing the keto function for a carboxylate
function or amide function thereof reduces the inhibition
potency considerably. The KI value of compounds 20 and 22,
in which the keto function has been replaced by a deactivated
carbonyl group, is 1600- and 8000-fold bigger, respectively, than
the KI value for the standard compound 17. The amide cannot be
considered to be an inhibitor at all because the KI is so much
bigger than the KM of the natural substrate. The inhibition
constant for the primary amide compound 21 could not be
determined because this inhibitor interfered with the Ehrlich’s
reaction, which is used to determine the amount of PBG
formed.[50] The comparison of the series of compounds in which
the modification of the keto function into an amide or into an
ester function has been made at the end of the chain or within
the chain is quite interesting. Introducing an amide group at the
end of the chain could mimic the imine or the iminium ion 7
formed between the two substrate molecules in the mechanism
Jordan I (see Scheme 4). The amide, and to some extent also the
ester in the chain, could be considered as a mimic for the
enamine or the enolate necessary for the ring closure reaction.
Comparing the inhibitors 10 and 12 with the compounds 13 and
15 shows that there is at most a slight difference between those
two arrangements of the functional groups. All of these
compounds are weak or even very weak inhibitors judged by
their KI values. A very interesting observation is the fact that
introducing the amino function at the end of the chain, with the
hope of adding another recognition site and thereby increasing
the affinity to the active site, does not influence the KI value in
the expected direction. The values for compounds 13 and 14 are
almost identical. In the case of the amides 15 and 16 the
introduction of the additional amino function transforms a weak
inhibitor into a compound that is no longer recognized by the
enzyme, an observation already reported by Leeper.[51] This
shows that we cannot expect simple additivity in our series of
inhibitors. If the interaction at one site is optimal, the trials to
improve the inhibition potency by adding additional functional
groups (in the hope of increasing the number of contacts) are
often not successful. The other clear conclusion is that for
inhibitors which interact at the A site of the enzyme the
replacement of the keto function by an amide group reduces
the inhibition potency substantially. As amides should be good
ligands for Lewis acids, this observation is surprising, but the
conclusion is similar as the one drawn from the introduction of
the fluoro substituent in the 5-position.
A final point has to be discussed in this context. The nitro
function seems to imitate the carboxylate very well. The nitro
analogues are often better recognized than the carboxylates
themselves. Those cases in which the introduction of a nitro
group has considerably enhanced the recognition have been
shown to be due to the interaction of the nitronate anion with
the active site of the enzyme. Careful titration of compounds 17
and 22 allowed us to determine the pKa values. It was necessary
to wait five minutes after each addition of base to establish the
equilibrium. The pKa values of 17 and 22 are 8.05 and 8.68,
respectively. This means that a considerable percentage of our
inhibitors is present in their deprotonated form. Without
spectroscopic information on the enzyme – inhibitor complex
we cannot be sure which form is present in the active site.
However, it seems reasonable to assume that the negatively
charged nitronate could be an excellent substitute for
Table 1. Inhibition of PBGS by substrate analogues in which the keto function
is modified.
Compound KI [mM] Inhibition type/remarks
HOOC
O
8 2 200 competitive
HOOC
O
F 9 85 competitive
HOOC OCH3
O
10 38 400 competitive
HOOC OH
O
11 12 500 competitive
HOOC NHCH3
O
12 36 400 competitive
HOOC O
O
13 24 500 competitive
HOOC O
O
NH2 14 18 200 competitive
HOOC N
H
O
15 18 800 competitive
HOOC N
H
O
NH2 16 >150 000 not detectable
Table 2. Inhibition of PBGS by substrate analogues containing a nitro
function instead of the carboxy group.
Compound KI [mM] Inhibition type/remarks
O2N
O
17 28 competitive
O2N
O
F 18 21 competitive
O2N OCH3
O
19 1 880 competitive
O2N OH
O
20 44 900 competitive
O2N NH2
O
21 – interference with the Ehrlich reaction
O2N NHCH3
O
22 222 800 competitive
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the carboxylate. This would be an additional reason why the
nitro compounds are generally such excellent inhibitors of
PBGS.[37]
The studies of a series of linear dicarboxylic acids containing
one or two keto functions had shown that PBGS is very sensitive
to the chain length. The sebacic acid derivatives, close analogues
of the postulated key intermediate of the Jordan I mechanism,
generally showed the highest inhibition efficiency.[41] It was also
shown that a three-point interaction was in general sufficient for
an excellent recognition of the inhibitor at the active site. Based
on these results we synthesized a series of analogues in which
we kept the keto function and the relative arrangements of the
functional groups constant (Table 3). Instead of the second keto
function, which should be recognized at the A site, we
introduced an amide group. Keeping this basic skeleton
constant, we varied the groups at the end of the chain from
carboxylate to an ester or nitro group. We synthesized most of
the variations of these end groups in order to analyze the
recognition selectivity at the two sites of the enzyme. Com-
pound 23, which contains two carboxylates, was our standard
for this series of tests. This compound was an irreversible
inhibitor, like the corresponding diketone or 4-oxosebacic acid
(30). Despite the substantial reduction of recognition of an
amide at the A site, which we had established before, compound
23 interacts strongly with the active site of PBGS. Exchanging the
carboxylate at the A site for a methyl ester function (!24)
reduced the interaction considerably and an uncompetitive
inhibitor with a KI value of 243 mM was obtained. The uncompe-
titive inhibition behavior is a good indication that our inhibitor
still interacts not only in the A site, but probably at both sites at
the same time. However, the potency of this inhibitor is strongly
reduced, as was expected from the studies of the substrate
analogues. Simply changing the position of the ester group from
the A site to the P site (!25) again resulted in an irreversible
inhibitor. This observation is compatible with a greater tolerance
for an ester function at the P site than at the A site. The amino
acids responsible for the interaction with the P-site carboxylate
are known from the X-ray crystallographic studies of PBGS
containing levulinate bound to the active site.[36, 38, 40] The
carboxy group of the levulinic acid forms three hydrogen bonds:
one with Tyr 329 and two with Ser 290. It can be envisaged that
with a methyl ester function only a partial disruption of the
hydrogen bonds occurs. This would explain the reduction in
recognition, rather than a total loss. The fact that the A-site
recognition seems to be less tolerant to esters is in favor of an
on – off mechanism for the recognition. The interaction could be
due to the fact that there are hydrogen bonds to one amino acid
only. This interpretation will have to be tested as soon as the
A site of PBGS can be identified by an X-ray crystallographic
analysis. Introducing a nitro function at the A site as in 26 and 27
still leads to irreversible inhibition. This result is expected and in
complete accordance with the results obtained with the
substrate analogues. Introduction of the nitro group at the
P site (!28 and 29) gives competitive/mixed inhibitors. These
inhibitors are slightly better than the inhibitor containing the
ester function at the A site (24), but their inhibition behavior and
their KI values of 20 and 30 mM, respectively, indicate that the
nitro group is by far not such a good group at the P site than it is
at the A site. It seems clear from these results that PBGS has two
distinct recognition mechanisms for the two carboxylates. The
P-site carboxylate can be replaced by an ester function with only
a slight loss in activity. Replacing the P-site carboxylate by a nitro
group is much less favorable. However, at the A site the nitro
group is by far the best group for obtaining a high affinity. The
ester function is not well tolerated at this part of the active site.
The tolerance of the P site to the ester function is compatible
with data available from the X-ray crystallographic structures.
For a rationalization of the inversed behavior of the A site, we
have to wait for results of X-ray crystallographic analyses that
should allow us to identify the groups responsible for the
recognition mechanism.
Finally, a minimal version of the analogues of the Jordan I
intermediate was tested (Table 4). 4-Oxosebacic acid (30) is an
irreversible inhibitor.[41] The nitro analogue 31 is a competitive
inhibitor with a KI value of 4900 mM. Probably this compound is
no longer recognized as an analogue of the intermediate, but it
is a substrate analogue with a long chain. This result is in
agreement with the observation reported above. When the keto
function is replaced by an amide function, very weak compet-
itive inhibitors like 32 and 33 are obtained. It is clear that the
absence of the keto function is not compensated for by the
correct chain length and the presence of two carboxylate
functions. The KI values are in the order of 20 mM, which means a
very weak inhibition.
Table 3. Inhibition of PBGS by analogues of the Jordan I key intermediate.
Compound KI [mM] Inhibition type/remarks
COOHHOOC
HN
O O
23 – irreversible
COOHH3COOC
HN
O O
24 243 uncompetitive
COOCH3HOOC
HN
O O
25 – irreversible
COOHO2N
HN
O O
26 – irreversible
COOCH3O2N
HN
O O
27 – irreversible
NO2H3COOC
HN
O O
28 20 competitive/mixed
NO2O2N
HN
O O
29 30 competitive/mixed
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Conclusion
We could show that substrate analogues in which the keto
function had been replaced is not well tolerated at the A site of
PBGS. However, an increase in the electrophilicity of the carbon
atom of the keto function increases the inhibition potency
considerably. This is compatible with an important interaction
with a nucleophile, but not really in accordance with an
interaction with a Lewis acid such as a ZnII ion. The amide
function, however, is well tolerated at the A site if it is
incorporated into an analogue of the Jordan I key intermediate.
This observation allowed us to distinguish the recognition
selectivities at both sites of the enzyme. The P site of the enzyme
tolerates the substitution of the carboxylate by an ester group.
The nitro function is accepted, but does not lead to an increase
in inhibition potential. This result can be interpreted on the basis
of the known structure of PBGS. On the other hand, the A site
accepts the replacement of the carboxylate by a nitro function
very well ; in most cases a considerable increase in the interaction
can be observed. Esters at the A site, however, are not tolerated.
This study clearly shows the importance of systematic studies
of specifically designed inhibitors to increase our knowledge
about the active site of enzymes. It is clear that definitive proof of
the observed results will have to wait until adequate X-ray
crystallographic structures become available. Finally, it is im-
portant to realize that we have interpreted our results on the
basis of the postulated key intermediates. However, at this stage
it is difficult—if not impossible—to distinguish between a
mechanism based on the binding of intermediates and a
mechanism based on the recognition of a bisubstrate com-
pound.[52]
Experimental Section
Biochemical studies
Materials: E. coli (CR 261) was a gift from C. Roessner (Texas A&M
University). Cultivation of E. coli and purification of PBGS were
performed as described previously.[53]
PBGS assay and determination of kinetic constants: The PBGS
assay is a colorimetric assay based on the reaction between PBG and
4-dimethylaminobenzaldehyde[50] (Ehrlich’s reagent). The assay for
E. coli PBGS contained 4 – 6.4 mg PBGS and the inhibitor in 1.5 mL of
0.1 M sodium phosphate buffer (NaH2PO4/Na2HPO4 mixture, pH 8.1,
12.3 mM mercaptoethanol, 10 mM MgCl2·6 H2O, 10 mM ZnCl2). The
preincubation took place at 37 8C for 30 – 45 min. The substrate was
added in varying concentrations and the solution was incubated for
14 min, after which the PBGS-catalyzed reaction was stopped by
adding 1 mL of the stop reagent (20 % (w/v) trichloroacetic acid,
10 mM HgCl2) at 0 8C. After centrifugation (4 min, 3600 g) 1 mL of the
supernatant was treated with 1 mL of Ehrlich’s reagent (1.1 g
4-dimethylaminobenzaldehyde in 20 mL perchloric acid and 35 mL
acetic acid). This solution was centrifuged (4 min, 3600 g) again. The
quantity of product formed was determined by measuring the
absorbance at 554 nm (e62 000 molÿ1 cmÿ1).
The type of inhibition was determined by using Eadie – Hofstee,
Lineweaver – Burk, and Hanes plots. The KI values shown in the
different tables are the average of at least three independent assays.
KI values were calculated from the apparent KM values deduced from
the hyperbolic plot, which is typical of Michaelis – Menten kinetics.
Estimation of the specific activity: Protein concentration was
estimated with the Bio-Rad Protein Assay using the color change of
Coomassie Brilliant Blue G-250. This color change is followed by
measuring the absorbance at 596 nm.[54] The concentration of PBGS
is deduced by comparison with a standard curve. Using this value
together with the rate of PBG formation allows the specific activity to
be calculated.
Dialysis assay: 4 – 6.4 mg PBGS were dissolved in 10 mL of 0.1 M
sodium phosphate buffer (see above). This solution (4 mL) was
placed in two different 5-mL tubes, one containing 2.5 – 10 mg of the
inhibitor, the second (without inhibitor) was used as a reference.
After 24 h at RT, the specific activities were determined. 1 mL of each
solution was placed in a dialysis tube and separately dialyzed against
1.5 L of 0.1 M sodium phosphate buffer (see above). After dialysis for
66 h at 4 8C, the specific activities were determined again.
Chemical syntheses
General : THF (purum, Fluka) was distilled over K and benzophenone
under N2; the other solvents (puriss. , Fluka) were used without
further treatment. TLC: silica gel 60 F254 plates (aluminium, 0.2 mm;
Merck). Flash column chromatography: silica gel 60 (0.04 – 0.063 mm,
Fluka) at ca. 0.2 bar. Determination of melting points: Büchi 510
apparatus, uncorrected. IR spectra: Perkin – Elmer 1720 X FT-IR
spectrophotometer; absorption bands given in cmÿ1. NMR spectra:
Bruker AMX-400 and Bruker Avance 400 (1H NMR: 400 MHz, 13C NMR:
100 MHz); Varian Gemini XL-200 and Varian Gemini 2000 (1H NMR:
200 MHz, 13C NMR: 50 MHz); Me4Si as external reference (d 0);
temperature: 298 K; all coupling constants J given in Hz. Mass
spectrometry: EI (70 eV) and CI (NH3 as ionisation gas): Nermag RC
30 – 10; ESI-MS and APCI-MS: Finnigan LCQ. HR-MS: Bruker
FTMS 4.7T BioAPEX II (ESI-MS, positive and negative mode). GC:
Perkin – Elmer SIGMA 3B, Dual FID Chromatograph, SE 54 column
(Macherey&Nagel, l 25 m, ID 0.32 mm, df 0.25 mm), P (program:
5 min at 70 8C, 70!150 8C at 8 8C minÿ1, 10 min at 150 8C). Elemental
analyses were performed by the Microanalytical Laboratory of Ciba-
Specialty SA, Marly, and by “l’Ecole d’Inge´nieur” of Fribourg.
Starting materials : (4-Nitro-2-oxo-1-butyl)ammonium chloride
(35),[55] monobenzyl succinate (36),[56] and (4-carboxy-2-oxo-1-butyl)-
ammonium chloride (1)[57] were synthesized according to the
literature. (4-Methoxycarbonyl-2-oxo-1-butyl)ammonium chloride
(37): A commercial sample (>98 %, Sigma) as well as a specifically
Table 4. Inhibition of PBGS by analogues of 4-oxosebacic acid (30).
Compound KI [mM] Inhibition type/remarks
COOHHOOC
O
30 – irreversible
COOHO2N
O
31 4 900 competitive
COOHHOOC
NH
O
32 22 900 competitive
NO2HOOC
NH
O
33 18 200 competitive/activator
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synthesized sample were used. 3-Methoxycarbonylpropionyl chlor-
ide (38) (purum, Fluka) as well as all the other starting materials were
commercially available (Fluka or Aldrich).
Levulinic acid (8), succinic acid (11), acetoxyacetic acid (13), N-
acetylglycine (15) and glycylglycine (16), 3-nitropropionic acid (20),
and monomethylsuccinate (10) were commercially available (Fluka
or Aldrich). 5-Fluorolevulinic acid (9),[58, 59] aminoacetic acid carboxy-
methylester (14),[60] and 4-nitrobutan-2-one (17)[61, 62] were synthe-
sized according to the literature.
The synthesis and characterization of the following starting materials
or intermediates is available as Supporting Information: 3-nitro-
propionyl chloride (39), 1-diazo-4-nitrobutanone (40), [ (4-benzyloxy-
carbonyl)-1-butyl]ammonium p-toluenesulfonate (41), [4-(methoxy-
carbonyl)-1-butyl]ammonium p-toluenesulfonate (42), [4-(benzyl-
oxycarbonyl)-2-oxo-1-butyl]ammonium p-toluenesulfonate (43),
methyl 5-[(3-nitropropionyl)amino]pentanoate (44), benzyl 5-{[3-
(benzyloxycarbonyl)propionyl]amino}pentanoate (45), benzyl 5-{[3-
(benzyloxycarbonyl)propionyl]amino}-4-oxopentanoate (46), methyl
5-{[3-(benzyloxycarbonyl)propionyl]amino}-4-oxopentanoate (47),
benzyl 5-{[3-(methoxycarbonyl)propionyl]amino}-4-oxopentanoate
(48), methyl 4-oxo-4-(2-oxocyclohexyl)butyrate (49), ethyl 9-bromo-
4-oxononanoate (50), intermediate 51, ethyl 9-nitro-4-oxononanoate
(52).
N-Methylsuccinamic acid (12): An 8 M solution of methylamine in
ethanol (5.5 mL, 44 mmol) was added to an ice-cooled solution of
succinic anhydride (2.0 g, 20 mmol) in ethanol (10 mL) and the
reaction mixture was stirred at 0 8C for 90 min and then for 1 h at RT.
Evaporation of the solvent, addition of 1 M HCl (40 mL) and ethyl
acetate (50 mL), saturation with NaCl, extraction with ethyl acetate
(850 mL), drying over MgSO4, filtration, and evaporation of the
solvent gave the crude product (1.65 g, 63 %). Subsequent purifica-
tion by recrystallization in THF/diethyl ether yielded 12 (1.0 g, 38 %)
as a white solid. M.p. 108 8C (ref. [64]: 111 8C). Rf 0.12 (CH2Cl2/
methanol, 9:1) ; IR (KBr plates, film): n˜ 3600 – 2400 (m), 3356 (vs),
2981 (m), 2929 (m), 2732 (m), 2642 (m), 2546 (m), 1715 (s), 1635 (s),
1569 (s), 1455 (m), 1422 (s), 1413 (s), 1370 (m), 1337 (m), 1277 (m),
1239 (s), 1179 (s), 1163 (s), 1085 (m), 1028 (m), 986 (m), 960 (m),
939 (m), 839 (m), 703 (m), 556 (m); 1H NMR (200 MHz, [D6]DMSO):
d2.28 (“t”, 3J3-2 6.2, 2 H, H2C(3)), 2.41 (“t”, 3J2-36.4, 2 H, H2C(2)),
2.55 (d, 3J5-HN 4.8, 3 H, H3C(5)), 7.76 (m, 1 H, HN) 12.06 (s, 1 H, HO);
13C NMR (50 MHz, [D6]DMSO): d 25.5 (C(5)) ; 29.2, 30.0 (C(2), C(3)) ;
171.4, 174.0 (C(1), C(4); MS (ESI, negative mode): m/z : 130 [Mÿ 1]ÿ ,
112 [Mÿ 1ÿH2O]ÿ , 86 [Mÿ1ÿCO2]ÿ .
1-Fluoro-4-nitro-butan-2-one (18):[63] Pyridine hydrofluoride (Fluka,
contains ca. 70 % HF; 10 mL) was added over 30 min to a solution of
1-diazo-4-nitrobutan-2-one (40) (1.43 g, 10 mmol) in diethyl ether
(15 mL) at 15 8C in a high-density polyethylene (HDPE) container
containing HF. The reaction mixture was stirred for 2 h at RT. Work-up
with water (20 mL) followed by extraction of the aqueous layer with
chloroform (6 50 mL), washing of the organic layers with anhy-
drous KF, filtration, and evaporation of the solvent gave the crude
product (610 mg, 45 %) as an orange liquid. Subsequent purification
by flash chromatography (silica gel; n-hexane/CH2Cl2 , 2:1) gave the
final product 18 (260 mg, 19 %) as a pure liquid (>99 % (GC), tr 9.6).
Rf 0.48 (ethyl acetate/n-hexane, 2:1) ; IR (KBr plates, film): n˜
3028 (w), 2973 (w), 2933 (w), 1745 (s), 1558 (vs), 1427 (m), 1398 (m),
1378 (s), 1082 (m), 1045 (m), 998 (m); 1H NMR (200 MHz, CDCl3): d
3.25 (td, 3J3-45.9, 4J3-F2.1, 2 H, H2C(3)), 4.72 (t, 3J4–3 6.0, 2 H,
H2C(4)), 4.92 (d, 2J1-F 47.4, 2 H, H2C(1)) ; 13C NMR (50 MHz, CDCl3): d
34.4 (C(3)), 67.9 (C(4)), 84.7 (d, 1J1-F184, 1 C, C(1)), 202.7 (d, 2J2-F21,
1 C, C(2)) ; 19F NMR (188 MHz, CDCl3): d 8.16 (t, 2JF-H547.7, 1 F,
FC(5)) ; MS (ESI, positive mode): 136 [M1] , 89 [M1ÿHNO2] ; HR-
MS: m/z : calcd for C4H6FNO3 158.02239 [MNa] , found 158.02211.
Methyl 3-nitropropionate (19): Oxalyl chloride (3.54 g, 21 mmol)
and DMF (1 drop) were added under N2 to an ice-cooled solution of
3-nitropropionic acid (2.51 g, 19.8 mmol) in CH2Cl2 (30 mL). The
reaction mixture was stirred for 15 min at 0 8C and then for 2 h 45 min
at RT. Half of the solvent was evaporated, the reaction mixture was
ice-cooled and methanol (5 mL) was added dropwise; the mixture
was stirred for 10 min at 0 8C and 20 min at RT. Evaporation of the
solvent gave a crude product as a yellowish liquid; purification by
bulb-to-bulb distillation (p0.5 – 0.07 mm Hg, T60 8C) yielded 19
(2.04 g, 78 %) as a colorless solid. Rf0.47 (ethyl acetate/n-hexane,
1:1) ; IR (KBr plates, film): n˜3009 (w), 2960 (w), 1739 (s), 1558 (vs),
1441 (s), 1407 (m), 1380 (s), 1342 (m), 1258 (m), 1218 (s), 1201 (s),
1181 (s), 872 (m), 850 (m); 1H NMR (200 MHz, CDCl3): d 4.64 (t,
3J3-2 6.2, 2 H, H2C(3)), 3.72 (s, 3 H, H3C(11), 2.97 (t, 3J3-2 6.0, 2 H,
H2C(2)) ; 13C NMR (50 MHz, CDCl3): d169.9 (C(1)), 69.6 (C(3)) ; 52.3
(C(11)), 30.7 (C(2)).
3-Nitropropionamide (21):[65] 3-Nitropropionyl chloride (39) (1.38 g,
10 mmol) was added to a 12 % ice-cooled aqueous solution of NH3
(10 mL). After 10 min, the reaction mixture was acidified to pH 1 with
32 % HCl saturated with NaCl. Extraction with ethyl acetate (8
40 mL), drying over MgSO4 , filtration, and evaporation of the solvent
gave the crude solid (1.02 g, 86 %). Subsequent purification by
preabsorbtion onto silica and purification by flash chromatography
(silica gel; ethyl acetate) yielded 21 (401 mg, 77 %) as a white solid.
Rf 0.14 (ethyl acetate). IR (KBr plates, film): n˜3394 (s), 3203 (m),
2973 (w), 2927 (w), 2855 (m), 2799 (m), 1710 (s), 1663 (s), 1630 (s),
1555 (vs), 1429 (s), 1402 (m), 1382 (m), 1310 (m), 1248 (m), 595 (m);
1H NMR (200 MHz, CDCl3): d 2.72 (t, 3J2-36.0, 2 H, H2C(2)), 4.66 (t,
3J3-2 6.0, 2 H, H2C(3)), 7.03 (s, 1 H, HN), 7.51 (s, 1 H, HN); 13C NMR
(100 MHz, CDCl3): d16.4 (C(6)), 28.2 (C(5)), 36.5 (C(2)), 42.5 (C(3)),
178.2 (C(1)), 210.7 (C(4)).
N-Methyl-3-nitropropionamide (22): A solution of 3-nitropropionyl
chloride (39) (543 mg, 3.95 mmol) in CH2Cl2 (4 mL) was added to an
8 M ice-cooled solution of methylamine in ethanol (1.1 mL, 8.7 mmol)
over 20 min. After 90 min the cooling bath was removed and the
reaction mixture was stirred for 2 h at RT. Addition of an 1 M aqueous
solution of HF (20 mL) and CH2Cl2 (30 mL), extraction with ethyl
acetate (330 mL), drying over MgSO4 , filtration, and evaporation of
the solvent gave the crude product (1.46 g, >100 %) as a brownish
oil. Subsequent purification by flash chromatography (silica gel;
ethyl acetate/n-hexane, 2:1) yielded 22 (401 mg, 77 %) as a white
solid. Rf 0.32 (CH2Cl2/ethyl acetate/methanol, 10:1:1) ; IR (KBr plates,
film): n˜3337 (s), 3305 (s), 3114 (w), 3022 (w), 2945 (m), 2924 (m),
2851 (w), 1674 (s), 1645 (vs), 1551 (s), 1416 (s), 1377 (s), 1340 (m),
1278 (s), 1248 (m), 1204 (m), 1165 (m), 1090 (m), 1030 (m), 952 (m),
874 (m), 738 (m), 581 (m), 492 (m); 1H NMR (400 MHz, CDCl3): d2.78
(d, 3J4-HN 4.8, 3 H, H3C(4)), 2.81 (t, 3J2-3 6.2, 2 H, H2C(2)), 4.67 (t,
3J3-2 6.1, 2 H, H2C(3)), 6.34 (s, 1 H, HN); 13C NMR (100 MHz, CDCl3,
DEPT): d 26.3 (C(4)), 32.2 (C(2)), 70.2 (C(3)), 169.0 (C(1)) ; MS (ESI,
positive mode): 155 [MNa] , 133 [M1] ; elemental analysis (%):
calcd for C4H8N2O3 (132.12): C 36.36, H 6.10, N 20.20; found: C 36.10,
H 6.15, N 21.76.
5-Amino-N-(3-carboxypropionyl)-4-oxopentanoic acid (23): A solu-
tion of the ester 46 (300 mg, 0.73 mmol) and of 10 % Pd/C (30 mg) in
THF (40 mL) was shaken under H2 (4 bar) for 20 h. The reaction
mixture was filtered through celite and the catalyst washed with THF
(40 mL). The filtrate was evaporated to give the crude product
(160 mg) as a white solid. Subsequent recrystallization from THF/
diethyl ether yielded 23 (85 mg, 61 %) as a white solid. M.p. 160 –
161 8C (ref. [66]: 197 – 199 8C); Rf 0.51 (ethyl acetate/methanol/
9
acetic acid, 8:1:1) ; IR (KBr): n˜3650 – 2300 (m) (3039), 3386 (m),
3341 (m), 2942 (m), 1724 (s), 1691 (vs), 1634 (s), 1530 (m), 1434 (m),
1410 (m), 1386 (m), 1305 (m), 1221 (m), 1195 (m), 630 (m); 1H NMR
(400 MHz, [D6]DMSO): d 2.36 – 2.47 (m, 6 H, H2C(2,7,8)), 2.63 (t,
3J3-2 6.3, 2 H, H2C(3)), 3.91 (d, 3J5-HN 5.4, 2 H, H2C(5)), 8.19 (t, 3JHN-5
5.5, 1 H, HN), 10.75 – 11.45 (s, 2 H, HO); 13C NMR (100 MHz, [D6]DMSO,
DEPT, HETCOR): d27.6 (C(2)) ; 29.2, 29.8 (C(7), C(8)) ; 34.1 (C(3)) ; 48.5
(C(5)) ; 171.5 (C(6)) ; 173.8, 173.9 (C(1), C(9)) ; 205.9 (C(4)) ; MS (ESI,
negative mode): m/z : ms 230 [Mÿ 1]ÿ , ms-ms (230) 212 [Mÿ 1ÿ
H2O]ÿ , ms-ms-ms (230, 212) 194 [Mÿ 1ÿ 2 H2O]ÿ , ms-ms-ms-ms
(230, 212, 194) 150 [Mÿ 1ÿ 2 H2OÿCO2]ÿ , ms-ms-ms-ms-ms (230,
212, 194, 150) 122 [Mÿ1ÿ2 H2OÿCO2ÿC2H4]ÿ ; elemental analysis
(%): calcd for C9H13NO6 (231.20): C 46.75, H 5.67, N 6.06; found: C
46.79, H 5.72, N 5.67.
5-{[3-(Methyloxycarbonyl)propionyl]amino}-4-oxopentanoic acid
(24): A solution of the ester 48 (335 mg, 1 mmol) and of 10 % Pd/C
(35 mg) in CH2Cl2 (40 mL) was shaken under H2 (4 bar) for 16 h. The
reaction mixture was filtered through celite and the catalyst washed
with THF (20 mL). The filtrate was evaporated to give the crude
product (260 mg) as a white solid. The recrystallization from THF/n-
hexane yielded 24 (166 mg, 68 %) as a white solid. M.p. 103 – 104 8C;
Rf 0.22 (CH2Cl2/methanol, 9:1) ; IR (KBr): n˜3500 – 2500 (w) (3027),
3344 (m), 2958 (w), 2938 (w), 1733 (s), 1695 (s), 1641 (vs), 1521 (m),
1437 (m), 1411 (m), 1376 (m), 1354 (m), 1310 (m), 1196 (m), 1173 (m),
1140 (m), 631 (m), 493 (m); 1H NMR (400 MHz, [D6]DMSO): 2.40 (t,
3J2-3 6.4, 2 H, H2C(2)), 2.43 (“t”, 3J7-8 or 8-76.1, 2 H, H2C(7 or 8)), 2.50
(“t”, 3J8-7 or 7-8 6.6, 2 H, H2C(8 or 7)), 2.62 (t, 3J3-26.4, 2 H, H2C(3)), 3.57
(s, 3 H, H3C(10), 3.92 (d, 3J5-HN 5.6, 2 H, H2C(5)), 8.22 (t, 3JHN-5 5.5, 1 H,
HN) 11.2 – 13.0 (s, 1 H, HO); 13C NMR (100 MHz, [D6]DMSO): d27.6
(C(2)) ; 28.8, 29.7 (C(7), C(8)); 34.7 (C(3)) ; 48.5 (C(5)) ; 51.5 (C(10)) ; 171.3
(C(6)) ; 172.9 (C(9)), 173.8 (C(1)) ; 205.8 (C(4)) ; MS (ESI, negative mode):
m/z : ms 244 [Mÿ1]ÿ , 212 [Mÿ 1ÿCH4O]ÿ , ms-ms (244) 212 [Mÿ
1ÿCH3OH]ÿ , ms-ms-ms (244, 212) 194 [Mÿ 1ÿCH3OHÿH2O]ÿ , ms-
ms-ms-ms (244, 212, ms-ms-ms (244, 212) 194 [Mÿ1ÿCH4Oÿ
H2O]ÿ , ms-ms-ms-ms (244, 212, 194) 150 [Mÿ 1ÿCH4OÿH2Oÿ
CO2]ÿ , ms-ms-ms-ms-ms (244, 212, 194, 150) 122 [Mÿ 1ÿCH4Oÿ
H2OÿCO2ÿ (CO or C2H4)]ÿ ; elemental analysis (%): calcd for
C10H15NO6 (245.23): C 48.98, H 6.16, N 5.71; found: C 48.78,
H 6.27, N 5.82; HR-MS: m/z : calcd for C10H16NO6 246.09721, found:
246.09720.
3-{[4-(Methoxycarbonyl)-2-oxobutyl]carbamoyl}propionic acid
(25): A solution of the ester 47 (600 mg, 1.79 mmol) and of 10 %
Pd/C (60 mg) in CH2Cl2 (75 mL) was shaken under H2 (4 bar) for 20 h.
The reaction mixture was filtered through celite and the catalyst
washed with THF (100 mL). The filtrate was evaporated to give the
crude product (650 mg) as a white solid. The recrystallization from
THF/diethyl ether yielded 25 (350 mg, 80 %) as a white solid.
M.p. 107 8C; Rf0.22 (CH2Cl2/methanol, 9:1); IR (KBr): n˜3650 –
2500 (m), 3348 (s), 3063 (m), 3027 (m), 2958 (m), 2927 (m), 2858 (m),
1730 (s), 1718 (vs), 1697 (s), 1636 (vs), 1525 (s), 1441 (m), 1423 (m),
1394 (m), 1384 (m), 1357 (s), 1311 (m), 1286 (m), 1202 (s), 1184 (m),
1140 (m), 1107 (m), 978 (m), 635 (m), 537 (m), 492 (m); 1H NMR
(400 MHz, [D6]DMSO): d 2.38 – 2.44 (m, 4 H, H2C(7,8)), 2.49 (t,
3J2-3 6.6, 2 H, H2C(2)), 2.70 (t, 3J3-2 6.5, 2 H, H2C(3)), 3.58 (s, 3 H,
H3C(10)), 3.93 (d, 3J5-HN5.6, 2 H, H2C(5)), 8.19 (t, 3JHN-55.4, 1 H, HN);
13C NMR (100 MHz, [F6]DMSO): d27.2 (C(2)) ; 29.2, 29.9 (C(7), C(8)) ;
33.9 (C(3)) ; 48.5 (C(5)) ; 51.5 (C(10)) ; 171.5 (C(4)) ; 172.7 (C(9)) ; 173.9
(C(1)) ; 205.7 (C(6)) ; MS: m/z (%): 246 (6) [M1] , 228 (4) [MÿOH] ,
214 (8) [MÿCH3O] , 196 (10) [MÿCH5O2] , 168 (12) [MÿC2H5O3] ,
140 (4) [MÿC3H5O4] , 131 (12) [C5H9NO3] . , 115 (100) [C5H7O3] , 114
(16), 113 (40) [C5H7NO2]
. , 101 (27) [C4H5O3] , 87 (19) [C4H7O2] , 73
(12) [C3H5O2] , 55 (27); elemental analysis (%): calcd for C10H15NO6
(245.23): C 48.98, H 6.16, N 5.71; found: C 49.03, H 6.17, N 5.73.
5-(3-Nitropropionylamino)-4-oxopentanoic acid (26): A solution of
pig liver esterase (4 mg, 130 U mgÿ1) in (NH4)2SO4 buffer (3 M, pH 7.2;
0.4 mL) was added to a solution of the ester 27 (565 mg, 2.3 mmol) in
water (40 mL). The reaction mixture was maintained for 9 h at pH 7.2
by adding 0.3 M NaOH then acidified to pH 1.5 with 32 % HCl,
saturated with NaCl, and extracted with ethyl acetate (8 50 mL).
The organic layers were dried over MgSO4 and filtered, and the
solvent was evaporated to give the crude product (400 mg) as a
brown oil. Subsequent recrystallization from THF yielded 26 (154 mg,
29 %) as a white solid. M.p. 148 8C; Rf0.37 (CH2Cl2/methanol, 7:3) ; IR
(KBr): n˜ 3650 – 2400 (w) (3069), 3317 (s), 2967 (w), 2922 (w), 1723 (s),
1699 (s), 1650 (vs), 1550 (s), 1433 (m), 1422 (m), 1407 (m), 1398 (m),
1389 (m), 1270 (m), 1234 (m); 1H NMR (400 MHz, [D6]DMSO): d2.41
(t, 3J2-3 6.5, 2 H, H2C(2)), 2.63 (t, 3J3-2 6.5, 2 H, H2C(3)), 2.84 (t, 3J7-8
5.9, 2 H, H2C(7)), 3.97 (d, 3J5-HN 5.5, 2 H, H2C(5)), 4.69 (t, 3J8-76.2, 2 H,
H2C(8)), 8.40 (t, 3JHN-55.2, 1 H, HN); 13C NMR (100 MHz, [D6]DMSO):
d27.6 (C(2)), 31.2 (C(7)), 34.1 (C(3)), 48.5 (C(5)), 70.6 C(8), 169.0 C(6),
173.7 C(1), 205.4 C(4) ; MS (ESI, negative mode): m/z : ms 231 [Mÿ 1]ÿ ,
184 [Mÿ1ÿHNO2]ÿ , ms-ms (231) 184 [Mÿ1ÿHNO2]ÿ , ms-ms-ms
(231, 184) 166 [Mÿ1ÿHNO2ÿH2O]ÿ , 140 [Mÿ 1ÿHNO2ÿCO2]ÿ ,
112 [Mÿ 1ÿHNO2ÿCO2ÿC2H4]ÿ ; HR-MS: m/z : calcd for C8H12N2-
NaO6 255.058750, found: 255.058743.
Methyl 5-[(3-nitropropionyl)amino)]-4-oxopentanoate (27): The
acyl chloride 39 (808 mg, 6 mmol) was added dropwise to a solution
of 37 (1.1 g, 6 mmol) in CH2Cl2 (50 mL) under N2 at 0 8C, followed by
the addition of triethylamine (1.23 g, 12 mmol) over 30 min. The
reaction mixture was stirred for 1 h at 0 8C and 1 h at RT. Work-up
with 1 M HCl (30 mL) and CH2Cl2 (30 mL) followed by extraction of the
aqueous layer with CH2Cl2 (3 50 mL), drying of the organic layers
over MgSO4, filtration, and evaporation of the solvent gave the crude
product (990 mg) as a yellow solid. Subsequent recrystallization from
ethyl acetate yielded 27 (657 mg, 44 %) as a white solid. M.p. 96 8C;
Rf 0.51 (CH2Cl2/methanol, 9:1) ; IR (KBr): n˜ 3650 – 2800 (w),
3300 (s), 3104 (w), 3027 (w), 2984 (w), 2955 (w), 2921 (w), 2854 (w),
1744 (s), 1727 (s), 1650 (s), 1573 (m), 1552 (vs), 1442 (m), 1411 (m),
1403 (m), 1377 (m), 1366 (m), 1348 (m), 1282 (m), 1213 (m), 1181 (m),
1097 (m), 1031 (m); 1H NMR (400 MHz, [D6]DMSO): 2.63 – 2.67 (m, 2 H,
H2C(2)), 2.72 – 2.76 (m, 2 H, H2C(3)), 2.90 (t, 3J8-9 6.2, 2 H, H2C(8)), 3.66
(s, 3 H, H3C(6)), 4.21 (d, 3J5-HN4.7, 2 H, H2C(5)), 4.69 (t, 3J9-8 6.2, 2 H,
H2C(8)), 6.58 (s, 1 H, HN); 13C NMR (100 MHz, CDCl3): d27.5 (C(2)),
32.1 (C(8)), 34.5 (C(3)), 49.3 (C(5)), 51.9 (C(6)), 69.9 (C(9)), 168.3 (C(7)),
172.8 (C(1)), 203.7 (C(4)) ; MS (EI): m/z (%): 246 (3) [M] . , 215 (2) [Mÿ
CH3O] , 115 (29) [C5H7O3] , 87 (11), 85 (14), 84 (37) [C4H4O2]
. , 59 (22),
57 (14), 56 (13), 55 (100); elemental analysis (%): calcd for C9H14N2O6
(246.22): C 43.90, H 5.73, N 11.38; found: C 43.84, H 5.54, N 11.25.
Methyl [(4-nitro-2-oxobutyl)carbamoyl]propionate (28): The acyl
chloride 38 (808 mg, 6 mmol) was added dropwise to a solution of
35 (460 mg, 2.74 mmol) in CH2Cl2 (30 mL) under N2 at 0 8C, followed
by the addition of triethylamine (554 mg, 5.48 mmol) over 30 min.
The reaction mixture was stirred for 1 h at 0 8C and for 2 h at RT. Work-
up with 1 M HCl (40 mL) and CH2Cl2 (10 mL) followed by extraction of
the aqueous layer with CH2Cl2 (440 mL), drying of the organic
layers over MgSO4 , filtration, and evaporation of the solvent gave the
crude product (640 mg) as a yellow solid. Subsequent purification by
flash chromatography (silica gel; CH2Cl2/methanol, 9:1) and recrys-
tallization from ethyl acetate yielded 28 (280 mg, 37 %) as a white
solid. M.p. 101 – 102 8C; Rf0.52 (CH2Cl2/methanol, 9:1); IR (KBr): n˜
3700 – 2800 (w), 3284 (s), 3107 (m), 2951 (w), 2925 (m), 1737 (vs),
1641 (s), 1573 (s), 1551 (s), 1433 (s), 1419 (s), 1390 (s), 1356 (m),
1341 (m), 1277 (m), 1252 (m), 1193 (s), 1176 (s), 1104 (m), 1066 (m),
1035 (m), 1016 (m), 981 (m); 1H NMR (400 MHz, [D6]DMSO): d 2.43 –
2.47 (m, 2 H, H2C(2)), 2.50 – 2.54 (m, 2 H, H2C(3)), 3.11 (t, 3J8-95.8, 2 H,
H2C(8)), 3.58 (s, 3 H, H3C(5)), 3.99 (d, 3J6-HN5.7, 2 H, H2C(6)), 4.70 (t,
10
3J9-8 5.8, 2 H, H2C(8)), 8.27 (t, 3J6-HN 5.4, 1 H, HN); 13C NMR (100 MHz,
[D6]DMSO, HETCOR): d 28.8 (C(3)), 29.6 (C(2)), 35.6 (C(8)), 48.4 (C(6)),
51.4 (C(5)), 69.4 (C(9)), 171.4 (C(4)), 172.9 (C(1)), 204.0 C(7) ; MS (CI):
m/z (%): 247 (10) [M1] , 232 (5) [M1ÿCH3] . , 215 (2) [Mÿ
CH3O] , 201 (12), 200 (100) [MÿNO2] , 168 (13) [MÿCH4O3N] ,
132 (11) [C5H10NO3] , 115 (8) [C5H7O3] , 100 (5) [C4H4O3] , 55 (8) ;
elemental analysis (%): calcd for C9H14N2O6 (246.22): C 43.90, H 5.73, N
11.38; found: C 44.14, H 5.79, N 11.30.
3-Nitro-N-(4-nitro-2-oxobutyl)propionamide (29): The acyl chloride
39 (79 mg, 0.59 mmol) was added to a suspension of 35 (100 mg,
0.59 mmol) in THF (30 mL) under N2 at 0 8C, followed by the addition
of triethylamine (1 g, 10 mmol) over 30 min. The reaction mixture
was stirred for 1 h at 0 8C and for 1 h at RT. Work-up with 1 M HCl
(30 mL) and diethyl ether (50 mL) followed by saturation with NaCl
and extraction of the aqueous layer with ethyl acetate (6 30 mL),
drying of the organic layers, filtration, and evaporation of the solvent
gave the crude product (130 mg) as a yellow solid. Subsequent
purification by flash chromatography (silica gel; n-hexane/ethyl
acetate, 4:1) yielded 29 (41 mg, 30 %) as a white solid. M.p. 129 –
130 8C; Rf 0.56 (CH2Cl2/methanol, 9:1) ; IR (KBr): n˜ 3700 – 2800 (m),
3293 (s), 3103 (w), 2973 (w), 2917 (w), 1732 (s), 1683 (m), 1651 (s),
1561 (s), 1541 (vs), 1426 (s), 1409 (m), 1398 (m), 1376 (s), 1357 (m),
1278 (m); 1H NMR (400 MHz, [D6]DMSO): d 2.85 (t, 3J2-3 5.9, 2 H,
H2C(2)), 3.12 (t, 3J6-75.7, 2 H, H2C(6)), 4.04 (d, 3J4-HN 5.6, 2 H, H2C(4)),
4.70 (t, 3J3-2 or 7-65.9, 2 H, H2C(3 or 7)), 4.71 (t, 3J7-6 or 3-2 5.8, 2 H, H2C(7
or 3)), 8.45 (t, 3JHN-4 5.4, 1 H, HN); 13C NMR (100 MHz, [D6]DMSO): n˜
31.2, 35.6 C(2), C(6) ; 48.4 (C(4)) ; 69.4, 70.6 (C(3), C(7)) ; 169.2 (C(1)) ;
203.6 (C(3)) ; MS (ESI, positive mode): m/z : 256 [MNa] , 251
[MNH4] , 234 [M1] , ms-ms (234) 187 [M1ÿHNO2] , ms-ms-ms
(234, 187) 140 [M1ÿ2 HNO2] , ms-ms-ms-ms (234, 187, 140)
122 [M1ÿ2 HNO2ÿH2O] ; elemental analysis (%): calcd for
C8H12N2O6 (232.19): C 36.06, H 4.75, N 18.02; found: C 36.09, H 4.86,
N 17.70.
4-Oxodecandioic acid (30): A solution of 87 % potassium hydroxide
(2.3 g, 41.5 mmol) in water (2 mL) was heated to 100 8C and the
diketone 49 (2.2 g, 10.4 mmol) was added. After 3 min the solution
was cooled with an ice bath, and water (5 mL) and 32 % HCl (5 mL)
were added. A white solid precipitated from the acidified solution
which was filtered to give the crude product (1.85 g) as a white solid.
Subsequent recrystallization from THF/n-hexane yielded 30 (1.71 g,
76 %) as a white solid. M.p. 107 8C (ref. [67]: 109 – 110 8C); Rf0.52
(ethyl acetate/methanol/acetic acid, 7:2:1) ; IR (KBr): n˜3650 –
2300 (m), 2938 (m), 1698 (vs), 1413 (m), 1295 (m), 1246 (m),
1216 (m), 1106 (m), 938 (m); 1H NMR (400 MHz, [D6]DMSO, COSY):
1.18 – 1.26 (m, 2 H, H2C(7)), 1.45 (qi, 3J6-5 3J6-7 7.8, 2 H, H2C(6)), 1.47
(qi, 3J8-7 3J8-97.6, 2 H, H2C(8)), 2.18 (t, 3J9-8 7.4, 2 H, H2C(9)), 2.38 (t,
3J2-3 6.4, 2 H, H2C(2)), 2.41 (t, 3J5-67.3, 2 H, H2C(5)), 2.62 (t, 3J3-2 6.5,
2 H, H2C(3)), 12.02 (s, 2 H, HO); 13C NMR (100 MHz, [D6]DMSO,
HETCOR): d 23.0 (C(6)) ; 24.4 (C(8)) ; 27.8 (C(2)) ; 28.2 (C(7)) ; 33.6
(C(9)) ; 36.7 (C(3)) ; 41.7 (C(5)) ; 173.9, 174.6 (C(1), C(10)); 209.2 (C(4)) ;
MS (EI): m/z (%): 217 (2) [M1] , 199 (7) [MÿOH] , 181 (6) [M1ÿ
2 H2O] , 153 (7), 143 (8) [MÿC3H5O2] , 125 (29) [MÿC3H7O3] , 116
(47) [C5H8O3]
. , 101 (41) [C5H9O2] , 98 (95) [C5H6O2]
. , 97 (30), 73 (77)
[C3H5O2] , 69 (100), 55 (55); calcd for C10H16O5 216.23.
9-Nitro-4-oxononanoate (31): A solution of pig liver esterase (3 mg,
130 U mgÿ1) in (NH4)2SO4 buffer (3 M, pH 7.2; 0.3 mL) was added to a
solution of the ester 52 (360 mg, 1.47 mmol) in water (40 mL). The
reaction mixture was maintained for 5 h at pH 7.2 by adding 0.2 M
NaOH, then acidified to pH 1 with 32 % HCl, saturated with NaCl and
extracted with ethyl acetate (6 50 mL). The organic layers were
dried over MgSO4, filtered, and the solvent was evaporated to give
the crude product (320 mg) as a liquid. Subsequent purification by
flash chromatography (silica gel; CH2Cl2/methanol, 96:4) yielded 31
(186 mg, 58 %) as a white solid. M.p. 62 – 63 8C; Rf 0.26 (CH2Cl2/
methanol, 9:1) ; IR (KBr): n˜ 3600 – 2400 (m) (3043), 2938 (m),
2893 (m), 2869 (m), 1722 (s), 1704 (s), 1551 (vs), 1474 (m), 1438 (m),
1411 (s), 1399 (s), 1389 (s), 1360 (m), 1336 (m), 1254 (m), 1233 (m),
1224 (vs), 1191 (m), 1152 (m), 1108 (m), 1075 (m), 911 (m), 633 (m);
1H NMR (400 MHz, CDCl3): d 1.36 (“qi”, 3J7-6 3J7-8 7.8, 2 H, H2C(7)),
1.62 (tt, 3J6-7 7.8, 3J6-5 7.2, 2 H, H2C(6), 1.99 (tt, 3J8-77.7, 3J8-9 7.0,
2 H, H2C(8)), 2.47 (t, 3J5-6 7.2, 2 H, H2C(5)), 2.59 – 2.62 (m, 2 H, H2C(2)),
2.67 – 2.70 (m, 2 H, H2C(3)), 4.36 (t, 3J9-8 7.0, 2 H, H2C(9)), 9.7 – 11.0 (s,
1 H, HO); 13C NMR (100 MHz, CDCl3): d 22.7 (C(6)) ; 25.6 (C(7)) ; 27.0
(C(8)) ; 27.7 (C(2)) ; 36.7 (C(3)) ; 41.9 (C(5)) ; 75.3 (C(9)) ; 178.7 (C(1)) ;
208.3 (C(4)) ; MS (ESI, negative mode): m/z : ms 216 [Mÿ 1]ÿ , ms-ms
(216) 169 [Mÿ1ÿHNO2]ÿ , ms-ms-ms (216, 169) 151 [Mÿ 1ÿ
HNO2ÿH2O]ÿ , 125 [Mÿ 1ÿHNO2ÿCO2]ÿ , 107 [Mÿ1ÿHNO2ÿ
H2OÿCO2]ÿ ; HR-MS: m/z : calcd for C9H15NNaO5 240.0842,
found: 240.0844.
5-[(3-Carboxypropionyl)amino]pentanoic acid (32): A solution of
the ester 45 (3.05 g, 7.7 mmol) and of 10 % Pd/C (300 mg) in CH2Cl2
(120 mL) was shaken under H2 (4 bar) for 20 h. The reaction mixture
was filtered through celite and the catalyst washed with THF (40 mL).
The filtrate was evaporated to give the crude product (1.77 g) as a
white solid. The recrystallization from THF/diethyl ether yielded 32
(1.29 g, 77 %) as a white solid. M.p. 141 8C; Rf0.52 (CH2Cl2/
methanol/acetic acid, 8:1:1) ; IR (KBr): n˜3650 – 2300 (m), 3315 (s),
3070 (s), 2964 (s), 2882 (m), 1693 (vs), 1629 (s), 1552 (s), 1473 (m),
1463 (m), 1431 (s), 1321 (s), 1271 (m), 1203 (s), 927 (m), 680 (m);
1H NMR (400 MHz, [D6]DMSO): d 1.33 – 1.41 (m, 2 H, H2C(4)), 1.43 –
1.51 (m, 2 H, H2C(3)), 2.18 (t, 3J2-3 7.3, 2 H, H2C(2)), 2.27 (t, 3J7-8 7.1,
2 H, H2C(7)), 2.38 (“t”, 3J8-7 6.9, 2 H, H2C(8)), 3.01 (td, 3J5-4 6.9, 3J5-HN
5.5, 2 H, H2C(5)), 7.83 (t, 3JHN-55.5, 1 H, HN), 10.8 – 11.9 (s, 2 H, HO);
13C NMR (100 MHz, [D6]DMSO, DEPT, HETCOR): d 22.1 (C(3)) ; 28.8
(C(4)) ; 29.6 (C(8)) ; 30.3 (C(7)) ; 33.6 (C(2)) ; 38.3 (C(5)) ; 171.0 (C(6)) ;
174.1, 174.6 (C(1), C(9)) ; MS (CI): m/z (%): 218 (100) [M1] , 200 (50)
[MÿOH] , 182 (23) [M1ÿ 2 H2O] ,174 (36) [M1ÿCO2]), 118 (31)
[C4H8NO3] , 100 (82) [C4H6NO2] ; elemental analysis (%): calcd for
C9H15NO5 (217.22): C 49.76, H 6.96, N 6.45; found: C 50.13, H 7.02, N
6.06; HR-MS: m/z : calcd for C9H15NNaO5 240.08424, found:
240.08422.
5-[(3-Nitropropionyl)amino]pentanoic acid (33): A solution of pig
liver esterase (3 mg, 130 U mgÿ1) in (NH4)2SO4 buffer (3 M, pH 7.2;
0.3 mL) was added to a solution of the ester 44 (1.2 g, 5.17 mmol) in
water (50 mL). The reaction mixture was maintained for 4 h at pH 7.3
by adding 0.5 M NaOH, then acidified at pH 1.5 with 32 % HCl,
saturated with NaCl and extracted with ethyl acetate (450 mL). The
organic layers were dried over MgSO4 and filtered, and the solvent
was evaporated to give the crude product (1.01 g) as an orange solid.
Subsequent recrystallization from THF/diethyl ether yielded 33
(810 mg, 72 %) as a white solid. M.p. 81 8C; Rf0.52 (ethyl acetate/
methanol, 2:1) ; IR (KBr): n˜3600 – 2400 (m), 3298 (s), 3071 (m),
2948 (m), 2878 (m), 1692 (s), 1638 (s), 1551 (vs), 1477 (m), 1464 (m),
1416 (m), 1377 (m), 1334 (m), 1280 (m), 1218 (m), 1192 (m), 924 (m),
872 (m), 681 (m); 1H NMR (400 MHz, [D6]DMSO): d 1.35 – 1.42 (m,
2 H, H2C(4)), 1.45 – 1.52 (m, 2 H, H2C(3)), 2.20 (t, 3J2-3 7.3, 2 H, H2C(2)),
2.73 (t, 3J7-8 6.0, 2 H, H2C(7)), 3.04 (td, 3J5-47.0, 3J5-HN 5.3, 2 H,
H2C(5)), 4.68 (t, 3J8-76.0, 2 H, H2C(8)), 8.04 (t, 3JHN-5 5.3, 1 H, HN),
12.00 (s, 1 H, HO); 13C NMR (100 MHz, [D6]DMSO, HETCOR): d 21.9
(C(3)), 28.5 (C(4)), 31.4 (C(7)), 33.2 (C(2)), 38.2 (C(5)), 70.7 (C(8)), 168.3
(C(6)), 174.4 (C(1)) ; MS (CI): m/z (%): 236 (50) [M18] , 219 (100)
[M1] , 201 (10) [MÿOH] , 187 (15), 172 (21) [MÿNO2] , 101 (15);
elemental analysis (%): calcd for C8H14N2O5 (218.21): C 44.03, H 6.47, N
12.84; found: C 44.24, H 6.53, N 12.67.
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